SecBot SecBot

BBIO

BridgeBio Pharma, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001743881 Biotech & Drug Discovery
$77.36 −0.94 (−1.20%)
Nov 16 4:00 PM ET · prev $78.30
Market cap
$15.2B
Large cap
Consensus
Buy
90% Buy or better · 29 analysts
Median target
🔒 Subscribers only
1 year
+15.6%
from $66.90 · Nov 17
30 days
+13.9%
from $67.94
52-week range
$63.30–90.17
−14% from high · low Oct 13
Avg volume 20D
2.97M
shares / day
Short interest
20.85M
≈10.7% of shares · +4.2%
Days to cover
7.1
at average volume
Insider net
−$22.4M
0 buyers · 5 sellers · since Jun 22
New fund stakes
3
Q2 2026 13F · 4 exits
Filing reports
23
analyzed by SecBot
SecBot read BULLISH 15 reports · 90 days
Balance 0 bearish · 7 bullish · 1 mixed · 7 neutral oldest → newest, height = score
Avg score ·High conf. 11/15 ·Next FDA decision date, Nov 27, 2026

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    5 insiders sold $22.4M.

  • InstitutionsMIXED

    Q2 2026: 48 added (3 new), 34 trimmed or exited. Largest new: Point72 Asset Management, $113.6M, Qube Research & Technologies $54.2M.

  • AnalystsBULLISH

    26 of 29 rate it Buy or better.

  • Short sellersSTEADY

    Short interest +4.2% to 20.85M shares. 7.1 days to cover, ≈10.7% of shares.

  • TrendUPTREND

    10% above its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 29.

Who's buying

13F· Q2 2026
3
new positions
4
exits
$184.6M
in new stakes
FundMoveSharesValue
BlackRock, Inc.TRIM10,287,156$766.2M
WELLINGTON MANAGEMENT GROUP LLPDOUBLED5,308,924$395.4M
D. E. Shaw & Co., Inc.ADD3,633,007$270.6M
GEODE CAPITAL MANAGEMENT, LLCTRIM3,418,419$254.7M
JANE STREET GROUP, LLCADD2,934,193$218.5M
JPMORGAN CHASE & COADD2,397,995$173.2M
ADAGE CAPITAL PARTNERS GP, L.L.C.DOUBLED2,252,000$167.7M
PRICE T ROWE ASSOCIATES INC /MD/TRIM1,726,383$128.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

29 analysts
Buy 90% rate it Buy or better
Strong Buy6Buy20Hold3Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Nov 13, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Nov 2, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Oct 30, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Oct 30, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Oct 21, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Oct 19, 2026Citigroup
MAINTAIN
MAINTAINNeutral
Congressional trades
BBIO trades disclosed by members of Congress, with disclosure delay.
1 members · 7 buys / 1 sells
DateMemberType AmountDisclosed
Nov 2, 2026 Gilbert CisnerosDHouse BRIDGEBIO PHARMA INC BUY $1K–$15K Nov 10, 2026 +8d
Oct 27, 2026 Gilbert CisnerosDHouse BRIDGEBIO PHARMA INC BUY $1K–$15K Nov 10, 2026 +14d
Sep 29, 2026 Gilbert CisnerosDHouse BRIDGEBIO PHARMA INC SELL $1K–$15K Oct 12, 2026 +13d
May 11, 2026 Gilbert CisnerosDHouse BRIDGEBIO PHARMA INC BUY $1K–$15K Jun 8, 2026 +28d
Apr 29, 2026 Gilbert CisnerosDHouse BRIDGEBIO PHARMA INC BUY $1K–$15K May 8, 2026 +9d
Mar 19, 2026 Gilbert CisnerosDHouse BRIDGEBIO PHARMA INC BUY $1K–$15K Apr 7, 2026 +19d
Mar 18, 2026 Gilbert CisnerosDHouse BRIDGEBIO PHARMA INC BUY $1K–$15K Apr 7, 2026 +20d
Mar 3, 2026 Gilbert CisnerosDHouse BRIDGEBIO PHARMA INC BUY $1K–$15K Apr 7, 2026 +35d

Insider ledger

Form 4
$0
bought · 0 insiders
$22.4M
sold · 5 insiders
DateInsiderTypeValue
Oct 30, 2026
Apuli Maricel
Chief Accounting Officer
Oct 30, 2026
SELL$145.7K
Sep 17, 2026
Kumar Neil
Chief Executive Officer
Sep 17, 2026
SELL$601.9K
Sep 17, 2026
Kumar Neil
Chief Executive Officer
Sep 17, 2026
SELL$89.0K
Aug 19, 2026
Kumar Neil
Chief Executive Officer
Aug 19, 2026
SELL$152.4K
Aug 19, 2026
Kumar Neil
Chief Executive Officer
Aug 19, 2026
SELL$679.3K
Aug 19, 2026
Kumar Neil
Chief Executive Officer
Aug 19, 2026
SELL$8.6K
Aug 18, 2026
Kumar Neil
Chief Executive Officer
Aug 18, 2026
SELL$154.2K
Aug 18, 2026
Kumar Neil
Chief Executive Officer
Aug 18, 2026
SELL$1.2M

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q-$0.37-$0.62–-$0.15-2.1%$338.1M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 12, 2026 SEC
Farallon Capital Management filed an amended Schedule 13G disclosing a 7.3% passive stake in BridgeBio Pharma as of…
SC 13G/A · Impact 3/10
Nov 11, 2026 Other
BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026
PALO ALTO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeB
Nov 9, 2026 SEC
In Q3 2026, 13 institutional investors accumulated $112.8M in net new BBIO positions, led by Citigroup (+$46M)…
INST-CLUSTER · Impact 4/10
Nov 6, 2026 Press
BridgeBio Pharma granted 147,578 restricted stock units to 80 new employees as an inducement material to their…
Impact 2/10
Nov 2, 2026 Congress
Gilbert Cisneros buy
$1,001 - $15,000 · House
Oct 30, 2026 Insider
Apuli Maricel sold 2,000 shares
Chief Accounting Officer @ $72.85 ($145.7K)
Oct 29, 2026 SEC
BridgeBio reported Q3 2026 total revenues of $353.2M, up 193% YoY from $120.7M, driven by $253.2M in U.S. Attruby net…
8-K · Impact 6/10
Oct 27, 2026 Congress
Gilbert Cisneros buy
$1,001 - $15,000 · House

Short side

FINRA· Oct 30, 2026
20,846,164
shares short
+4.2%
vs prior settlement
7.1
days to cover
≈10.7%
of shares outstanding
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Upcoming
Recent
Nov 11, 2026
Press release
BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026
PALO ALTO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage…
Nov 9, 2026
Press release
BridgeBio to Participate in November and December Investor Conferences
PALO ALTO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage…
Nov 6, 2026
Activist
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical…
Nov 3, 2026
Press release
BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026
PALO ALTO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage…
Oct 29, 2026
Earnings
BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates
- $353.2 million in total third quarter revenues, primarily comprised of $253.2 million of U.S. Attruby net product revenue (up approximately $31…
Reddit
Recent posts
All social signals and their track records

Washington

Corporate Lobbying

24 lobbying filings and 6 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

SecBot reports

23 filings · 15 press releases · 4 bullish · 2 bearish · 5 mixed · 12 neutral
All BBIO filing & press-release reports (38)